Research Output per year
Fingerprint Dive into the research topics where Julian R Molina is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 21 Similar Profiles
Non-Small Cell Lung Carcinoma
Medicine & Life Sciences
Lung Neoplasms
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Pemetrexed
Medicine & Life Sciences
Small Cell Lung Carcinoma
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1996 2019
1
Citation
(Scopus)
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, N., Santana-Davila, R. & Molina, J. R., Aug 1 2019, In : Mayo Clinic proceedings. 94, 8, p. 1623-1640 18 p.Research output: Contribution to journal › Review article
Open Access
Early Detection of Cancer
Non-Small Cell Lung Carcinoma
Programmed Cell Death 1 Receptor
Epidemiology
Lung Neoplasms
1
Citation
(Scopus)
PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses
Sarkar Bhattacharya, S., Thirusangu, P., Jin, L., Roy, D., Jung, D., Xiao, Y., Staub, J., Roy, B., Molina, J. R. & Shridhar, V., Oct 1 2019, In : Cell Death and Disease. 10, 10, 725.Research output: Contribution to journal › Article
Open Access
Phosphofructokinase-2
Endoplasmic Reticulum Stress
Fructose
Food
Cell Death
20
Citations
(Scopus)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., Price, K. A., Molina, J. R., Pagliaro, L. C., Halfdanarson, T. R., Grothey, A. F., Markovic, S. N., Nowakowski, G. S., Ansell, S. M. & Wang, M. L., Jan 1 2019, In : JAMA Oncology.Research output: Contribution to journal › Article
CD274 Antigen
Meta-Analysis
Clinical Trials
Incidence
Odds Ratio
11
Citations
(Scopus)
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial
Herbst, R. S., Baas, P., Perez-Gracia, J. L., Felip, E., Kim, D. W., Han, J. Y., Molina, J. R., Kim, J. H., Dubos Arvis, C., Ahn, M. J., Majem, M., Fidler, M. J., Surmont, V., De Castro, G., Garrido, M., Shentu, Y., Emancipator, K., Samkari, A., Jensen, E. H., Lubiniecki, G. M. & 1 others, , Feb 1 2019, In : Annals of Oncology. 30, 2, p. 281-289 9 p.Research output: Contribution to journal › Article
docetaxel
Confidence Intervals
Survival
Neoplasms
Proteins
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
Jazieh, K., Molina, J. R., Allred, J., Yin, J., Reid, J. M., Goetz, M. P., Lim, V. S., Kaufmann, S. H. & Adjei, A., Jan 1 2018, (Accepted/In press) In : Investigational New Drugs.Research output: Contribution to journal › Article
tipifarnib
Farnesyltranstransferase
Epidermal Growth Factor
Protein-Tyrosine Kinases
Maximum Tolerated Dose